What Else?

MAIA is also issuing unregistered warrants for the purchase of the same number of shares. This offering, expected to close around November 17, with H.C. Wainwright & Co. as the exclusive placement agent, is estimated to generate roughly $4 million for MAIA.

The company plans to allocate these funds for general operations, research and development in the cancer therapy field. The warrants, exercisable after six months at $1.86 per share, will expire five and a half years from the issuance date.

See Also: Asia Closes Higher, Europe Markets Trade In Green As Inflation Eases

According to data from Benzinga Pro, MAIA has a 52-week high of $5.22 and a 52-week low of $1.42.